BAM
RNAM

Belpointe Asset Management’s Avidity Biosciences RNAM Stock Holding History

Belpointe Asset Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,984
Closed -$44K – 3832
2022
Q4 		$44K Buy
+1,984
New +$29.6K ﹤0.01% 1685

Other funds holding RNAM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Belpointe Asset Management's RNAM Position: Q1 2023 in Review

Belpointe Asset Management sold out of Avidity Biosciences (RNAM) in Q1 2023, closing a stake of 1,984 shares — an estimated $44K sold.

Belpointe Asset Management first reported a position in RNAM in Q4 2022 and held it in 1 quarter. The position peaked at $44K in Q4 2022. 139 funds tracked by Wall St. Rank hold RNAM as of Q1 2023.

  • Belpointe Asset Management reported no remaining Avidity Biosciences position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 1,984 Avidity Biosciences shares in Q1 2023, an estimated $44K.
  • Belpointe Asset Management first reported a position in Avidity Biosciences in Q4 2022 and held it in 1 quarter.
  • Belpointe Asset Management's Avidity Biosciences position peaked at $44K in Q4 2022.
  • 139 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.